Recently, novel SS18::SSX and SSX C-terminus–specific antibodies have shown high sensitivity and specificity for synovial sarcoma, offering the potential for immunohistochemistry to replace molecular genetics in most cases. The gene discussed is SSX2; the disease is synovial sarcoma.